Mesoblast Receives European Green Signal to Conduct Trial of Stem Cell Injection

by Kathy Jones on  September 8, 2011 at 5:41 PM Genetics & Stem Cells News
RSS Email Print This Page Comment bookmark
Font : A-A+

Australian drug manufacturer Mesoblast has been given the go-ahead signal by the European Medicines Agency to conduct a trial for its stem cell injection, Revascor, which promises to provide more efficient treatment for patients who have suffered from acute heart attacks.
 Mesoblast Receives European Green Signal to Conduct Trial of Stem Cell Injection
Mesoblast Receives European Green Signal to Conduct Trial of Stem Cell Injection

Revascor has been developed using stem cells extracted from the bone marrow of healthy young adults and the company said that initial studies have shown the injection to reduce the damage caused by heart attacks by more than 50 percent.

The company has been given clearance to conduct the trial in Europe with 225 patients expected to take part in the study including those from Belgium, England and the Netherlands.

Mesoblast revealed that it expected the product to hit the market within the next five years.

Source: Medindia

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Stem Cells - Cord Blood Stem Cells - Fundamentals Parkinsons Disease Surgical Treatment Genetics and Stem Cells Bone Marrow Transplantation 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor
Advertisement

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive